Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

UK begins trial of multivariant Covid-19 vaccine booster; details here

PTI
Updated: September 22nd, 2021, 08:00 IST
in Coronavirus, International
0
COVID-19: Covovax vaccine trials begin in India

Representational pic

Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

London: A phase one trial of a multivariant Covid-19 vaccine booster drug has got underway among participants aged over 60 in the UK.

The trial, involving GRT-R910, has been launched by US pharmaceutical company Gritstone in collaboration with the University of Manchester and Manchester University NHS Foundation Trust. It will explore the potential of the drug to boost the immune response of first-generation COVID-19 vaccines to a wide array of variants of Sars-Cov-2, which cause Covid-19.

Also Read

Egypt’s el-Sissi calls Trump’s Mideast plan ‘last chance’ for peace

Egypt’s el-Sissi calls Trump’s Mideast plan ‘last chance’ for peace

3 hours ago
Israel releases nearly 2,000 Palestinian prisoners under Gaza ceasefire deal

Israel releases nearly 2,000 Palestinian prisoners under Gaza ceasefire deal

3 hours ago

“We think GRT-R910 as a booster vaccination will elicit strong, durable, and broad immune responses, which are likely to be critical in maintaining protection of this vulnerable elderly population who are particularly at risk of hospitalisation and death,” said Professor Andrew Ustianowski, Chief Investigator for the study from the North Manchester General Hospital.

“We now know the immune response to first generation vaccines can wane, particularly in older people. Coupled with the prevalence of emerging variants, there is a clear need for continued vigilance to keep COVID-19 at bay,” he said.

Part of Gritstone’s CORAL programme, GRT-R910 is described as a self-amplifying mRNA second-generation SARS-CoV-2 vaccine – or SAM for short, which delivers antigens from both the spike and non-spike proteins.

“Our SAM COVID-19 vaccine is designed to drive robust CD8+ T cell responses, in addition to strong neutralising antibody responses, offering the promise of longer lasting immunity,” said Andrew Allen MD, Co-Founder, President and Chief Executive Officer of Gritstone.

He added: “Since viral surface proteins like the spike protein are evolving and sometimes partially evading vaccine-induced immunity, we designed GRT-R910 to have broad therapeutic potential against a wide array of SARS-CoV-2 variants by also delivering highly conserved viral proteins that may be less prone to genetic variation in the virus.

“Our hypothesis is that a different vaccine such as GRT-R910 might complement the primary immune response from pre-existing vaccination with a first generation COVID vaccine in such a way that it would provide more benefit than an additional dose of the same vaccine.”

The trial will take place at the National Institute for Health Research (NIHR) Manchester Clinical Research Facility at Manchester Royal Infirmary, part of Manchester University NHS Foundation Trust (MFT), and delivered by the Research and Innovation Vaccine Team.

Supported by Health Innovation Manchester, the trial is expected to recruit 20 volunteers, with data evaluating the vaccine expected in the first quarter of 2022. Results from the preclinical studies leading up to the development of the vaccine will be jointly published by Gritstone and the National Institutes of Health later in the year.

“We’re tremendously excited that this promising vaccine is to be trialed here in Manchester. As the only European site for this study, it is testament to the way our academic and clinical researchers have come together as part of the ‘One Manchester R&I’ approach to answer the questions the world needs answers to,” said Professor Ian Bruce, Chair of the Manchester COVID-19 Research Rapid Response Group (RRRG).

“Though the vaccine is being trialled in the over 60s, future studies will also examine its efficacy in other-vulnerable populations. If successful, we feel it has the potential to have play a significant role in the battle against COVID-19, which has so devastated vulnerable populations across the globe,” he said.

The study will examine dose, safety, tolerability, and immunogenicity of GRT-R910 at two dose levels at least four months after the second administration of their initial vaccine. GRT-R910 is also being investigated as part of a US National Institute of Health sponsored Phase 1 study.

PTI 

Tags: booster shotCOVID-19UKvaccine
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Sarfraz Ahmad

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Spinoj Pattnaik

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
#MyPaperBagChallenge

Matrumangal Jena

December 12, 2019
#MyPaperBagChallenge

Priyabrata Mohanty

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Mandakini Dakua

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Akshaya Kumar Dash

December 12, 2019
#MyPaperBagChallenge

Adrita Bhattacharya

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Narendra Kumar

December 12, 2019
#MyPaperBagChallenge

Arya Ayushman

December 12, 2019
#MyPaperBagChallenge

Sibarama Khotei

December 12, 2019
#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019
#MyPaperBagChallenge

Vandana Singh

December 12, 2019
#MyPaperBagChallenge

Sitakanta Mohanty

December 12, 2019
#MyPaperBagChallenge

Parbati Mohanty

December 12, 2019
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
#MyPaperBagChallenge

Dibya Ranjan Das

December 12, 2019
#MyPaperBagChallenge

Kamana Singh

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Surya Sidhant Rath

December 12, 2019
#MyPaperBagChallenge

Ankita Balabantray

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019
#MyPaperBagChallenge

Nishikant Rout

December 12, 2019
#MyPaperBagChallenge

Mrutyunjaya Behera

December 12, 2019
#MyPaperBagChallenge

Swarit Praharaj

December 12, 2019

Archives

Editorial

Peacemakers

Trump-Maria
October 14, 2025

There is rejoicing as peace has started to return to the heart of the war-ravaged Middle East, and a ceasefire...

Read moreDetails

Afghanistan As Friend

Afghanistan
October 13, 2025

Some politicians and feminists are screaming that it is outrageous that the Taliban could display its misogyny on Indian soil...

Read moreDetails

Stalled Promise

October 12, 2025

Thirty five years ago, India chose to go down two paths, on both of which it remains. The first path...

Read moreDetails

Trade to Tirade

October 11, 2025

It started, as many big stories do these days, with a tweet. A blunt social media post by a mid-sized...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST